Abstract Body

“Unusual” Hepatitis C virus (HCV) subtypes in patients from Africa and Asia origin have been associated with a lower sustained virological response(SVR) to DAAs. This can be ascribed to polymorphisms at relevant amino acid positions compared to the most sensitive subtype in the same genotype. Using the global SHARED network, we aimed to assess the prevalence of RAS and RAS patterns at failure among unusual HCV subtypes, defined as GT1 non1a/b, GT2 non2a/b, GT3 non3a, GT-4 non4a/d, GT5, and GT6.

We extracted data from the SHARED database of patients who did not achieve SVR.  Only patients who failed DAA regimens recommended by EASL guidelines were included. Geno- and subtype were sequence-derived, and analyses grouped by subtype. RAS were analysed at positions according to the 2018 EASL guidelines.    

We analysed 60 unusual subtypes among DAA failures, including: GT2c(n=8), GT3b(n=6), GT3h(n=7) and GT4r(n=10) followed by GT4v(n=3), GT2q,3k,4g,4o, and 6q(n=2, each), and GT1l,2j,3g,4b,4f,4k,4q,4t, 6h, 6p,6r and 6xe(n=1, each). Patients failed; SOF/DCV(n= 14), SOF/VEL +/- RBV(n=13), and EBR/GZR(n=10), SOF/LDV +/- RBV(n=10), G/P(n=5) or other regimens(n=2). At failure, all patients harbored NS5A RASs regardless of their subtype, with a mean number of 3 NS5A RAS per sample.  Interestingly, failures with GT6h/p/r/xe carried 5 to 6 NS5A polymorphisms possibly associated with reduced NS5A inhibitor susceptibility. All GT3h failures harbored a S62M RAS with unknown impact, 71% of which were combined with the Y93H/F. All GT4r failures harbored L28M/T/V RAS in association with L30R with or without L31M/F. All GT-3b and GT3g harbored the A30K+L31M+S62D/E/I combination. Additionally, among NS3 failures RAS at position 168(D168V/N/E) were observed in 50% of patients(n=6/12). Importantly, combinations of several NS3 RAS were detected in specific subtypes(GT4g with R155Q+A156T/I/V+D168N, GT6q with A156F+D168V in patients failing GZP/ELB and G/P respectively). The S282T variant in NS5B occurred in 20% of GT4r patients(n=1).

Unusual subtypes(mainly but not only GT3b, 3h, and 4r) may be overrepresented among failures, suggesting lower SVR rates due to the presence of polymorphisms. In-depth characterization of these subtypes is crucial, in Africa and Asia where these subtypes are common as well as in countries of immigration from these regions. Our results emphasize the need for identification of RAS in these subtypes and their in vitro drug susceptibilities.